Genprex, Inc.

LSE:0A8I Stock Report

Market Cap: US$4.0m

Genprex Valuation

Is 0A8I undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0A8I when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate 0A8I's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate 0A8I's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0A8I?

Key metric: As 0A8I is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 0A8I. This is calculated by dividing 0A8I's market cap by their current book value.
What is 0A8I's PB Ratio?
PB Ratio2.4x
BookUS$1.66m
Market CapUS$4.03m

Price to Book Ratio vs Peers

How does 0A8I's PB Ratio compare to its peers?

The above table shows the PB ratio for 0A8I vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average0.7x
BSFA BSF Enterprise
0.7xn/aUK£3.0m
LLAI LungLife AI
0.4x101.0%UK£2.8m
TCF Theracryf
1x30.7%UK£2.3m
VAL ValiRx
0.6xn/aUK£2.2m
0A8I Genprex
2.4x-16.3%US$4.0m

Price-To-Book vs Peers: 0A8I is expensive based on its Price-To-Book Ratio (2.4x) compared to the peer average (0.7x).

Price to Book Ratio vs Industry

How does 0A8I's PB Ratio compare vs other companies in the GB Biotechs Industry?

4 CompaniesPrice / BookEstimated GrowthMarket Cap
DEST Destiny Pharma
0.3x-15.5%US$5.85m
BDRX Biodexa Pharmaceuticals
0.5xn/aUS$4.42m
LLAI LungLife AI
0.4x101.0%US$3.48m
VAL ValiRx
0.6xn/aUS$2.80m
No more companies available in this PB range
0A8I 2.4xIndustry Avg. 2.8xNo. of Companies7PB02.44.87.29.612+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: 0A8I is good value based on its Price-To-Book Ratio (2.4x) compared to the UK Biotechs industry average (2.8x).

Price to Book Ratio vs Fair Ratio

What is 0A8I's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0A8I PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio2.4x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 0A8I's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

hVIVO

UK£134.7m

Operates as a pharmaceutical service and contract research company in the United Kingdom.

HVO

UK£0.20

7D

-16.8%

1Y

2.1%

Formycon

€844.9m

A biotechnology company, develops biosimilar drugs in Germany and Switzerland.

0W4N

€48.35

7D

2.8%

1Y

-24.9%

Regeneron Pharmaceuticals

US$81.0b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

0R2M

US$749.80

7D

1.3%

1Y

-7.7%